Vaccine Information Statement for Hepatitis A Vaccine; Revised Instructions for Use of Vaccine Information StatementsJames D. Seligman
has effective treatment and a vaccine Hepatitis C has a cure and is preventable Latest News See all news > Momentum builds for universal hepatitis B testing Hepatitis Australia has welcomed strong national media interest in the call for a universal offer of hepatitis B testing. Media Relea...
Correspondence toPierre Van Damme. Editor information Editors and Affiliations Vaccine Research Centre, University of Tampere Medical School, Tampere, Finland Timo Vesikari Vaccine & Infectious Disease Institute, Centre for the Evaluation of Vaccination, University of Antwerp, Antwerpen, Belgium Pierre Van ...
Viral hepatitis represents a disease entity caused by at least five unrelated viruses whose primary tissue tropism is the hepatocyte. Hepatitis A is an acute self-limited disease resulting from infection with hepatitis A virus (HAV). Infection with hepat
2012, Vaccine Citation Excerpt : In 2003, an expert group published a consensus statement on long-term protection of hepatitis A vaccines, which involved a non-systematic information search [14]. Based on existing data and models (e.g. Iwarson et al. [15] and Landry et al. [16]), the...
In developed countries, low incidence and low vaccine coverage have led to a high proportion of susceptible individuals, which creates a potential for expanded hepatitis A outbreaks when contaminated products are widely distributed [8]. The development of sensitive, reliable techniques for the detection...
Although a vaccine for HEV has been developed, it is only licensed in China. Additionally, no effective, non-teratogenic and specific treatments against HEV infections are currently available. Although progress has been made in characterizing HEV biology, the scarcity of adequate experimental platforms...
Some individuals may benefit from receiving hepatitis A immune globulin (IG) in addition to the hepatitis A vaccine. This is something that your healthcare provider can advise you on. If you are already vaccinated for hepatitis A, good news! You already have protection and do not nee...
Unfortunately, no further progress has been reported on the development of this vaccine. Another hepatitis E vaccine, HEV 239, is a 26-kDa recombinant polypeptide that corresponds to 368–606 aa of the capsid protein from a HEV-1 strain. Being licensed for use in individuals aged >16 years,...
HEV 239 (Hecolin®) is a hepatitis E vaccine that contains a recombinant 239-amino acid protein corresponding to amino acid 368–606 of ORF2 protein of genotype 1 HEV, expressed inEscherichia coli[6,7]. It is approved in China (2011) and Pakistan (2021) and has recently received market...